Alzheimer disease

>

Latest News

European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population / image credit Joanne Pike Alzheimer's Association
European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population

November 15th 2024

The EMA recommendation excludes from treatment adults who are homozygous for the ApoE ε4 gene, a decision that the US Alzheimer's Association does not support, said the president/CEO.

Adjusted Donanemab Dosing Lowers ARIA-E Risk in Early Alzheimer Disease: Daily Dose / image credit: ©New Africa/AdobeStock
Adjusted Donanemab Dosing Lowers ARIA-E Risk in Early Alzheimer Disease: Daily Dose

November 13th 2024

Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock
Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose

November 5th 2024

Eisai Announces Submission of Rolling BLA for SQ Autoinjector-Delivered Lecanemab image credit dementia ©Billion Photos/Shutterstock.com
Eisai Announces Completion of Rolling BLA for SQ Autoinjector-Delivered Lecanemab

November 1st 2024

New Data Support Lecanemab Long-Term Dosing in Alzheimer Disease and Benefit In Earliest Stage / image credit ©Lightspring/Shuttestock.com
New Phase 3 Data Suggest Benefits of Early Lecanemab Initiation on Alzheimer Disease Progression, Support Long-Term Safety

October 31st 2024

<123
© 2024 MJH Life Sciences

All rights reserved.